Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

(2013) Ajay Vora et al.   LANCET ONCOLOGY

Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis

(2012) V. Gupta et al.   BLOOD

Has MRD monitoring superseded other prognostic factors in adult ALL?

(2012) M. Bruggemann et al.   BLOOD

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

(2012) M. S. Topp et al.   BLOOD

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

(2012) N. Gokbuget et al.   BLOOD

Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia

(2012) Hagop Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL

(2012) R Garand et al.   LEUKEMIA

Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia

(2012) B Denys et al.   LEUKEMIA

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

(2012) J J M van Dongen et al.   LEUKEMIA

Acute Lymphoblastic Leukemia: Monitoring Minimal Residual Disease as a Therapeutic Principle

(2012) Monika Brüggemann et al.   SEMINARS IN ONCOLOGY

Redefining Transplant in Acute Leukemia

(2011) Rob Sellar et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: when and how

(2011) J.-M. Ribera   HAEMATOLOGICA

Current Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia

(2011) Adele K. Fielding   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Modern Therapy of Acute Lymphoblastic Leukemia

(2011) Renato Bassan et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

(2010) V. Conter et al.   BLOOD

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

(2009) R. Bassan et al.   BLOOD

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993

(2009) Bella Patel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

(2009) M Brüggemann et al.   LEUKEMIA

Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study

(2008) Jerzy Holowiecki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Optimal management of adults with ALL

(2008) Jacob M. Rowe   BRITISH JOURNAL OF HAEMATOLOGY

Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible

(2008) Michael Norbert Dworzak et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Treatment of Adult Acute Lymphoblastic Leukemia

(2008) Nicola Gökbuget et al.   SEMINARS IN HEMATOLOGY